{
    "1722601182646927660": {
        "attachments": {
            "media_keys": [
                "3_1722601179782254592"
            ]
        },
        "author_id": "62465691",
        "created_at": "2023-11-09T13:05:00.000Z",
        "edit_history_tweet_ids": [
            "1722601182646927660"
        ],
        "entities": {
            "annotations": [
                {
                    "end": 117,
                    "normalized_text": "Eccogene",
                    "probability": 0.4625,
                    "start": 110,
                    "type": "Other"
                }
            ],
            "urls": [
                {
                    "description": "AstraZeneca and Eccogene have entered into an exclusive licence agreement for ECC5004, an investigational oral once-daily glucagon-like peptide 1 receptor agonist (GLP-1RA) for the treatment of obesity, type-2 diabetes and other cardiometabolic conditions. Preliminary results from the Phase I trial have shown a differentiating clinical profile for ECC5004, with good tolerability and encouraging glucose and body weight reduction across the dose levels tested compared to placebo. Sharon Barr, Executive",
                    "display_url": "learn.az/6012utHz4",
                    "end": 228,
                    "expanded_url": "https://learn.az/6012utHz4",
                    "start": 205,
                    "status": 200,
                    "title": "AstraZeneca licenses novel agent for the treatment of cardiometabolic conditions and obesity",
                    "unwound_url": "https://www.astrazeneca.com/media-centre/press-releases/2023/agreement-with-eccogene-for-clinical-stage-glp-1ra.html?utm_source=twitter&utm_medium=acquisition+2023&utm_term=12138&utm_content=cvrm",
                    "url": "https://t.co/NDgPqn0qu6"
                },
                {
                    "display_url": "pic.twitter.com/pyQmik5Iyq",
                    "end": 252,
                    "expanded_url": "https://twitter.com/AstraZeneca/status/1722601182646927660/photo/1",
                    "media_key": "3_1722601179782254592",
                    "start": 229,
                    "url": "https://t.co/pyQmik5Iyq"
                }
            ]
        },
        "id": "1722601182646927660",
        "lang": "en",
        "public_metrics": {
            "bookmark_count": 0,
            "impression_count": 2828,
            "like_count": 6,
            "quote_count": 0,
            "reply_count": 6,
            "retweet_count": 2
        },
        "text": "Intended for investor or business / science media. \n\nWe are excited that today we announced an agreement with Eccogene to develop next generation therapeutic options for these patients. \n\nLearn more here: https://t.co/NDgPqn0qu6 https://t.co/pyQmik5Iyq"
    }
}